Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Supernus Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Attention Deficit Disorder With Hyperactivity; Conduct Disorder

Treatments: Drug: SPN-810

Study type: Interventional

Funder types: Industry

Identifiers

NCT00626236

810P201

Details and patient eligibility

About

The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.

Full description

This will be a randomized, multicenter, parallel group, dose-ranging safety and tolerability study in children with ADHD and persistent serious conduct problems. The target subjects are healthy male or female children aged 6 to 12 years, inclusive, with a diagnosis of ADHD with persistent serious conduct problems. To determine eligibility for the study, subjects will undergo an initial screening visit. Seventy-two subjects will be randomized in the study; assuming a 17% dropout rate, it is anticipated that 60 subjects will complete the study. The study will consist of a Screening Period (within 28 days prior to the first dose administration), a Titration Period of 2 to 5 weeks, a Maintenance Period of 6 weeks, and a Safety Follow-up, which will be performed 30 days after the final study visit. The total subject duration in the study will be 16 to 19 weeks depending on the treatment group assignment. The total study duration is anticipated to be 15.5 months. A total of 72 subjects will be randomized based on weight at baseline, to 1 of 4 treatment groups.

Enrollment: 78 patients

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Healthy pediatric male or female subjects, age 6 to 12 years.
2. Diagnostic and Statistical Manual of Mental Disorders - IV -Text Revision (DSM-IV-TR) diagnosis of ADHD.
3. NCBRF-TIQ disruptive behavior disorder subscale 27 or greater at baseline; AND a score of 2 or more on at least 1 of the following 3 items of the conduct problem subscale: knowingly destroys property, gets in physical fights, physically attacks people.
4. IQ greater than 71.

Exclusion criteria

1. Current or lifetime diagnosis of bipolar disorder, post-traumatic stress disorder, personality disorder, or psychosis not otherwise specified.
2. Currently meeting DSM-IV-TR criteria for major depressive disorder, obsessive compulsive disorder, or pervasive developmental disorder.
3. Any other anxiety disorder as primary diagnosis.
4. Use of anticonvulsants, antidepressants, lithium, carbamazepine, valproic acid, or cholinesterase inhibitors within 2 weeks of baseline.
5. Unstable endocrinological or neurological conditions which confound the diagnosis or are a contraindication to treatment with antipsychotics.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

78 participants in 4 patient groups

Treatment 1

Experimental group

Description:

Treatment 1: SPN-810 5mg/day for subjects \<30kg and 10mg/day for subjects ≥30kg

Treatment:

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Treatment 2

Experimental group

Description:

Treatment 2: SPN-810 10mg/day for subjects \<30kg and 20mg/day for subjects ≥30kg.

Treatment:

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Treatment 3

Experimental group

Description:

Treatment 3: SPN-810 15mg/day for subjects \<30kg and 30mg/day for subjects ≥30kg.

Treatment:

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Treatment 4

Experimental group

Description:

Treatment 4: SPN-810 20mg/day for subjects \<30kg and 40mg/day for subjects ≥30kg.

Treatment:

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810

Drug: SPN-810